Savara (NASDAQ:SVRA) Shares Up 4.8%

Shares of Savara Inc (NASDAQ:SVRA) traded up 4.8% during mid-day trading on Wednesday . The company traded as high as $4.50 and last traded at $4.41. 233,532 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 1,211,780 shares. The stock had previously closed at $4.21.

Wall Street Analyst Weigh In

Several research firms have weighed in on SVRA. Oppenheimer boosted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Guggenheim upped their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. JMP Securities reduced their price target on shares of Savara from $10.00 to $9.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 13th. Evercore ISI decreased their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Savara in a research note on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara presently has a consensus rating of “Buy” and a consensus price target of $11.17.

Savara Stock Performance

The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The firm has a market capitalization of $610.80 million, a PE ratio of -12.27 and a beta of 0.97. The firm’s 50 day moving average price is $4.42 and its 200-day moving average price is $4.55.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, research analysts expect that Savara Inc will post -0.44 EPS for the current year.

Institutional Trading of Savara

Several institutional investors have recently modified their holdings of SVRA. Jump Financial LLC boosted its stake in Savara by 320.3% during the 4th quarter. Jump Financial LLC now owns 136,700 shares of the company’s stock worth $642,000 after purchasing an additional 104,174 shares during the last quarter. Superstring Capital Management LP purchased a new stake in Savara during the 4th quarter valued at about $3,827,000. Wellington Management Group LLP acquired a new stake in Savara in the 4th quarter valued at about $9,683,000. Sivia Capital Partners LLC acquired a new stake in Savara in the 4th quarter valued at about $169,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Savara by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after purchasing an additional 10,381 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.